Who
Zhengbin Yao
Director
Company insider
Files Form 4 as: Director, Alumis; President and CEO, ArriVent BioPharma; Director, NexImmune; Chief Executive Officer, Viela Bio; Vice President of Research, Tanox.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $353K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 15 Feb 2006
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —3,553 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,528 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,528 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —3,553 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 30 Jul 2025filed 1 Aug 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,800 at $0.00 | filing |
| 3 Feb 2025filed 14 Feb 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —380,000 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,016 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,016 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,278 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,278 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS AlumisBiotechnology | SEC FORM 4 Code D | —23,529 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —23,529 | filing |
| 27 Jun 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,016 at $0.00 | filing |
| 5 Jul 2023filed 7 Jul 2023 | NexImmuneoption or derivative | SEC FORM 4 Code A | —44,983 at $0.00 | filing |
| 4 Apr 2023filed 6 Apr 2023 | NexImmuneoption or derivative | SEC FORM 4 Code D | —61,678 | filing |
| 4 Apr 2023filed 6 Apr 2023 | NexImmuneoption or derivative | SEC FORM 4 Code A | —61,678 | filing |
| 4 Apr 2023filed 6 Apr 2023 | NexImmuneoption or derivative | SEC FORM 4 Code D | —9,556 | filing |
| 4 Apr 2023filed 6 Apr 2023 | NexImmuneoption or derivative | SEC FORM 4 Code A | —9,556 | filing |
News
No headline names them, or the companies they trade most, lately.